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Abstract 
Objectives: 1) To compare the primary care consulting behaviour prior to diagnosis 
of people with Systemic Lupus Erythematosus (SLE) with controls, 2) to develop and 
validate a risk prediction model to aid earlier SLE diagnosis. 
Methods: 1,739 incident SLE cases practice-matched to 6,956 controls from the UK 
Clinical Practice Research Datalink. Odds ratios were calculated for age, gender, 
consultation rates, selected presenting clinical features and previous diagnoses in 
the 5 years preceding diagnosis date using logistic regression. A risk prediction 
model was developed from pre-selected variables using backward stepwise logistic 
regression. Model discrimination and calibration were tested in an independent 
validation cohort of 1,831,747 patients.  
Results: People with SLE had a significantly higher consultation rate than controls 
(median 9.2 vs 3.8/year) which was in part attributable to clinical features that occur 
in SLE. The final risk prediction model included the variables age, gender, 
consultation rate, arthralgia or arthritis, rash, alopecia, sicca, Raynaud’s, serositis 
and fatigue. The model discrimination and calibration in the validation sample was 
good (Receiver operator characteristic curve: 0.75, 95% CI 0.73-0.78). However, 
absolute risk predictions for SLE were typically less than 1% due to the rare nature 
of SLE. 
Conclusions: People with SLE consult their GP more frequently and with clinical 
features attributable to SLE in the five years preceding diagnosis, suggesting that 
there are potential opportunities to reduce diagnostic delay in primary care. A risk 
prediction model was developed and validated which may be used to identify people 
at risk of SLE in future clinical practice.   
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Significance and Innovation  
• People diagnosed with SLE consult their GP more than twice as frequently as 
controls on average in the 5 years prior to diagnosis  
• People diagnosed with SLE consult their GP with clinical features attributable 
to SLE in the five years preceding diagnosis 
• This suggests that there are potential opportunities to reduce diagnostic delay 
for people with SLE in primary care. 
• A risk prediction model has been developed and validated which may be used 
to identify people at risk of SLE in future clinical practice. 
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INTRODUCTION 
Systemic Lupus Erythematosus (SLE) is a multi-system autoimmune disease which 
can be life or organ-threatening. However, the initial symptoms can be non-specific 
and mimic other medical conditions, leading to diagnostic delay. A national Lupus 
UK survey (1) found a mean delay from first patient-reported symptom to diagnosis 
of 7.7 years. 50% of respondents had been given a previous diagnosis, most 
commonly rheumatoid arthritis (RA), but also undifferentiated connective tissue 
disease, renal disease and fibromyalgia. Ozbek et al.(2) reported a mean delay from 
first symptom to diagnosis of 21.8±30.3 months, with arthralgia being the most 
common presenting symptom (60%) and those with malar rash at presentation 
(12%) having the shortest time to diagnosis.  
It is not clear where delays between symptom-onset and SLE diagnosis occur. 
People with symptoms may delay presenting to primary care. There may be delayed 
recognition of the diagnosis amongst those presenting with symptoms, leading to 
delayed secondary care referral. The diagnosis might be delayed in primary or 
secondary care due to misattribution of symptoms to an alternative disease e.g. 
fibromyalgia or RA. It is likely that reducing this delay will enable diagnosis and 
treatment at an earlier stage before severe organ involvement has occurred, thus 
improving outcomes and reducing healthcare costs. For example, a Danish cohort of 
100 people with lupus nephritis followed for a median of 15 years found that delayed 
diagnosis and delayed intervention increased risk of progression to end-stage renal 
failure.(3) Furthermore a US health insurance database study found that diagnosis 
(defined as date of the first International Classification of Diseases (ICD)-9 code for 
SLE) delayed more than 6 months from symptom-onset (defined as the second 
diagnostic code for a symptom of SLE such as malar rash, photosensitivity, arthritis, 
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pleurisy or an ANA test in the 12 months prior to SLE diagnosis) lead to greater flare 
rates, healthcare utilisation and more insurance claims (4) suggesting that earlier 
diagnosis may enhance patient outcomes. 
We firstly aimed to examine consulting behaviour of SLE cases in primary care in the 
5 years preceding diagnosis compared to controls to ascertain if consulting 
behaviour was a predictor for earlier diagnosis. Secondly, we developed and 
validated a multivariable risk prediction model to establish whether primary care 
consultation patterns and clinical features could be used to diagnose SLE earlier.  
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METHOD 
Source population 
We used the Clinical Practice Research Datalink (CPRD), a longitudinal database of 
anonymised general practice records incepted in 1987 deemed to be representative 
of the UK population.(5) In January 2013 there were 660 practices contributing 
records for approximately 12 million people. The CPRD has been previously 
described and validated (6, 7), but in brief practices enter data on patient 
demographics, diagnoses, consultations and prescriptions using Vision Practice 
Management Software. Diagnoses are recorded using Read codes, a standard 
clinical terminology system used in general practice in the UK. Clinical information is 
entered contemporaneously during primary care consultations using Read codes 
and free text data. Only coded data were used for this study.  
Participants were males and females contributing data during 1st January 1999 to 
31st December 2012. They were eligible once their practice was contributing one 
year of data from practice registration.  
Independent Scientific Advisory Committee for MHRA Database Research approval 
was gained for this study on 4th June 2013 (Protocol 13_092). 
Study participants and study design 
Cases were adult (18-100 years) incident cases of SLE identified previously.(6) In 
brief, participants were selected as cases if they had one of 14 Read codes for SLE 
or a subtype (excluding cutaneous only lupus) newly diagnosed during 1st January 
1999 to 31st December 2012. Given that SLE is a rare disease we decided to 
include all cases with at least one code to maximise the sample size. GPs would be 
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unlikely to Read code a diagnosis of SLE without conﬁrmation from secondary care 
(personal communication, GD) and previous studies of other chronic autoimmune 
diseases have shown good accuracy in recording on the CPRD with positive 
predictive values >90% (8, 9). Date of first diagnosis was the index date. 
Cases were randomly allocated by practice into a development (two-thirds) or 
validation dataset (one-third).  
A case-control design was used for the development dataset as SLE is rare and this 
provided a straightforward approach for estimating odds ratios (OR) for clinical 
features in the exposure period. Four practice-matched controls per case were 
randomly selected from the non-SLE population. Eligible controls were aged 18-100 
years and contributing at least 12 months of study time. Controls were not age or 
gender matched so these factors could be included in the model. After selection, 
controls were given an index date the same as the matched case. The study period 
started at the latest of registration date or 5 years prior to the index date.  
A cohort design was used for model validation as this represented how the model 
would be used in practice and enabled direct calculation of predicted probabilities. 
The validation dataset included all practices containing the one-third of SLE cases 
plus all eligible non-SLE participants from those practices. For validation, predictor 
variables were assessed in the year preceding study entry and the outcome (index 
date) was assessed in the 1 to 5 years following study entry. Participants with less 
than one year of follow-up were excluded. Study entry for the validation cohort 
dataset was the latest of date of 18th birthday, registration date plus 1 year or 1st 
January 1999. For those participants with a consultation during follow-up, the first 
consultation date was chosen as the start date. For those participants without a 
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consultation and more than 5 years of follow-up a random start date was chosen 
using a random number function.  For those participants without a consultation and 
less than 5 years of follow-up study entry was the start date. Study exit was the 
earliest of index date (SLE diagnosis), death, transfer out of a participating practice, 
31st December 2012, date of birth plus 100 years or 5 years from study entry. 
(Supplementary figure 1). 
 
Predictor variables 
Age (in years) and gender were chosen as important risk factors for SLE (6) and 
were available for every eligible participant. Consultation rate was the mean number 
of consultations per year (total number of consultations during the study period 
divided by follow-up time in years). It was hypothesised that people with SLE would 
consult their GP more frequently prior to diagnosis than those without SLE. Important 
clinical features and diagnoses that may precede a diagnosis of SLE were 
considered by all authors and agreement was reached by consensus. The clinical 
features examined were: arthralgia or arthritis, rash, alopecia, fatigue, Raynaud’s 
phenomenon, sicca symptoms, nephrotic syndrome, serositis, general non-specific 
symptoms, myalgia or myositis, lymphopenia, anaemia, thrombocytopenia, 
miscarriage, thrombosis, fever, lymphadenopathy, abnormal weight loss, mouth 
ulcers, peripheral oedema, proteinuria, depression, psychosis, confusion, seizure, 
headache, transverse myelitis were coded as “present” or “absent”. Previous 
differential diagnoses considered were: fibromyalgia, chronic fatigue syndrome, RA, 
other connective tissue disease (CTD) or Epstein-Barr virus (EBV) and a family 
history (FH) of autoimmune disease was also ascertained. For objective 2 fewer 
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candidate predictor variables were chosen a priori for model development for 
practicality and so that a variable was less likely to be significant by chance. Age, 
gender, consultation rate, arthralgia or arthritis, rash, alopecia, fatigue, Raynaud’s 
phenomenon, sicca symptoms, nephrotic syndrome, serositis and general non-
specific symptoms were investigated. Consultations in the year preceding diagnosis 
were excluded as there was an increase in immunology blood tests and 
rheumatology referrals, therefore we hypothesised that GPs were considering the 
diagnosis of SLE and we aimed to investigate whether diagnosis could be made 
earlier. As the clinical feature variables were coded as either present or absent there 
were no missing data. 
Statistical analysis 
Objective 1: In the development dataset OR were calculated using logistic 
regression for each exposure variable. These were then adjusted for age, gender 
and consultation rate. Unconditional logistic regression was used as the cases and 
controls were only matched by practice and were felt to be a reasonable sample of 
people without SLE for an unmatched analysis. Using conditional logistic regression 
made little difference to the result. Clinical features recorded in two mutually 
exclusive exposure periods were explored; 0-1 years and 1-5 years preceding the 
index date. Differences between cases and controls in median time from clinical 
feature to index date were compared using the Mann-Whitney U test.  
Objective 2:  
Model development: Stepwise backward logistic regression used the candidate 
predictors to develop the prediction model. Age and gender were retained in the 
model as a priori predictors. Fractional polynomials (FP) were used to find the best 
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fitting transformations for continuous variables (age and consultation rate).(10, 11) 
The significance of each variable and interaction between age and gender was 
tested using likelihood ratio (LR) tests. Variables were retained in the model if the LR 
test was significant (P<0.05). Including the FPs and interaction terms there were 16 
candidate predictors and at least 10 events (cases) per candidate predictor in the 
development data indicating adequate sample size based on recommendations.(12) 
Model validation:  
To obtain the predicted risk score (risk_score) the β-coefficients for the model were 
applied with mean-centring in combination with a new α-coefficient. The new α- 
coefficient reflected the probability of SLE in the validation cohort using (13): 
α= ln (incidencenew/1-incidencenew)  
This recalibrated the α from the developed model to the validation dataset (as the 
development α was biased due to it being a case-control sample).  
The probability (p) of developing SLE in the validation dataset was calculated using: 
p=exp(risk_score)/(1+exp(risk_score)) 
The area under the receiver operating characteristic curve (ROC) tested model 
discrimination between those with and without the disease. Calibration was 
assessed with a calibration plot, graphically comparing the observed and predicted 
risk of SLE stratified by decile of predicted risk. Calibration-in-the-large and 
calibration slope statistic were calculated.(14) These should ideally be 0 and 1 
respectively. The sensitivity, specificity, positive predictive value (PPV) and negative 
predictive value (NPV) were calculated comparing the top 5 and 10% of risk as a 
threshold for triggering further investigation. 
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Data management and analysis was performed using StataMP4 software, version 13 
(Statacorp, Texas, USA). Multiple imputation was not required as complete data 
were available.   
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RESULTS 
There were 2,635 incident cases from 571 practices; 1,739 in the development 
dataset (matched to 6,956 controls) and 896 (from a cohort of 2,187,974 adults) in 
the validation dataset. 1,831,747 of the validation participants had at least one year 
of follow-up from study entry of which 365 cases were diagnosed between 1 and 5 
years and were therefore eligible for study inclusion. Table 1 shows the baseline 
demographics.  
 
Objective 1 
The OR for female gender was 5.23 (95% CI: 4.56-6.00, p<0.001). In the 5 years 
preceding diagnosis the median consultation rate per year was 9.2 (IQR: 5.4-14.7) 
for cases and 3.8 (IQR: 1.4-7.6) for controls (p<0.001). The OR was 1.098 (95% CI: 
1.089-1.106, p<0.001) i.e. for every additional consultation per year the odds of 
having SLE increased by 9.8%. Stratifying the time before diagnosis by year there 
remained a significant increase in consultation rate for cases in all 5 years 
(Supplementary Table 1).  
The OR for clinical features and diagnoses in the 5 years preceding diagnosis are in 
Table 2. Arthritis or arthralgia, rash, fatigue, headache and depression were the 
features which occurred most frequently in cases. Nephrotic syndrome, Raynaud’s, 
thrombocytopenia, a family history of RA or a previous diagnosis of other CTD 
discriminated most strongly between cases and controls.  Table 3 shows the 
comparison for 0-1 and 1-5 years preceding diagnosis.  
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Table 4 summarises the median time from clinical feature to index date. Among 
cases only nephrotic syndrome and thrombocytopenia were recorded within a year 
of diagnosis on average.  
 
Objective 2:  
Model development  
Table 5 gives the mutually adjusted ORs and β-coefficients for the final model. 
Nephrotic syndrome was excluded as there was only 1 case and no controls with this 
in the 1-5 years preceding diagnosis. Age and consultation rate were non-linear, 
therefore FP terms were used. All variables except general non-specific symptoms 
were significant at the 0.05 level. There was significant interaction between age and 
gender (p=0.0034) indicating that FP coefficients used to model the effect of age 
differed for men and women and therefore interaction terms were used. The ROC 
was 0.7850 (95% CI: 0.7733-0.7966).  
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Model validation 
The new α-coefficient (-8.5204) and the β-coefficients with mean-centring produced 
the following model: 
Risk score1= -8.5204 + femalegenderx1.3718 + arthritisx0.6273 + rashx1.1106 + 
alopeciax0.6763 + raynaudx2.1359 + siccax0.4458 + fatiguex0.3451 + 
serositisx0.49171 + (age2-48.98052) x0.0058 + [(age2 x ln(age))-(48.98052 x 
ln(48.9815))] x-0.0004 + [(rate+1.1921e-07/ 100)-0.5-0.06302-0.5] x-0.0018 + 
[ln(rate +1.1921e-07/ 100)- ln(0.06302)]x-0.0004 + (age2-48.98052) 
xfemalegenderx-0.0018 + [(age2 x ln(age))-(48.98052 x 
ln(48.9815))]xfemalegenderx0.0004 
 
Model discrimination was good (ROC 0.7538 (95% CI: 0.7295-0.7781)) (Figure 1a). 
The calibration plot showed good agreement between observed and predicted risks 
(Figure 1b). This was confirmed with the calibration-in-the-large statistic (-0.0334 
(95% CI: -0.1360-0.0692)) and calibration slope (1.1495 (95% CI: 1.0331-1.2659)). 
The 95% CI for the calibration slope was above 1 suggesting some miscalibration; 
however the absolute magnitude of this was very small. 
 
Using the top 10% as a threshold for defining high risk of SLE, the sensitivity was 
33.97%, specificity 90.01%, PPV 0.07% and NPV 99.99%. Using the top 5% the 
sensitivity was 23.84%, specificity 95.00%, PPV 0.09% and NPV 99.98%.  
                                            
1
 The best-fitting FP2 model powers for age at diagnosis were 2 and 2 i.e. age
2
 and age
2
 x ln(age) 
and for consultation rate were -0.5 and 0 i.e. rate
-1
 and ln(rate). Scaling was used for consultation rate 
where scaled rate = unscaled rate+1.1921e-07/100 and mean-centre was 6.3021. The mean-centre 
for age was 48.9805. 
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Used clinically, a 51 year old woman presenting to the GP three times in the past 
year with arthralgia, rash and Raynaud’s would have a probability of developing SLE 
in the subsequent 1-5 years of 0.0128 (top 5%). In contrast, a 33 year old man 
presenting to the GP once in the past year with a rash would have a probability of 
developing SLE of 0.0001 in the subsequent 1-5 years (bottom 90%). 
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DISCUSSION 
People diagnosed with SLE consulted their GP more than twice as frequently as 
controls on average in the 5 years prior to diagnosis, as judged by the median 
consultation rate (supplementary table 1). Compared with controls people with SLE 
were more likely to consult with clinical features suggestive of SLE, such as 
arthralgia or arthritis, rash, alopecia and Raynaud’s. The median time from clinical 
feature presentation to SLE diagnosis was greater than one year for all features 
except nephrotic syndrome and thrombocytopenia which are likely to prompt acute 
hospital admission or urgent diagnosis of SLE. This is the first study to develop a risk 
prediction model for SLE to identify SLE cases in the community. It had good 
discrimination and calibration with high specificity and NPV, but low sensitivity and 
PPV due to the rare nature of SLE.(6) 
Previous studies of early clinical features and other rheumatological diagnoses given 
prior to that of SLE have largely been small single-centre analyses reliant on patient 
recall following diagnosis.(1, 2, 15) One US military record study(16) found in 130 
people with SLE arthritis was the most frequent presenting symptom occurring a 
mean of 1.36 years before diagnosis. In comparison, our study was larger, from a 
more diverse population and included a control group. A Taiwanese insurance 
claims study (17) found increased use of medical care in the eight years preceding 
SLE diagnosis. A shorter time period was used for our study to increase the number 
of participants with complete data and increase the chance that clinical features were 
attributable to SLE. There is no primary care gate-keeper in Taiwan such as in the 
UK so these consultations represented self-referrals to specialists. This study 
considered diagnoses using ICD-9 headings such as “Disorders of the eye and 
adnexa” rather than presenting symptoms such as “sicca” as in our study. A UK 
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paediatric study (18) found that nephritis, Black or Asian ethnicity and referral from a 
paediatrician to a paediatric rheumatologist were independent predictors of quicker 
SLE diagnosis. However, their cohort was smaller, only included children and relied 
on patient or parent recall of symptoms. Our early symptoms findings support the 
recent primary care campaign “Think LUPUS and refer” supported by Lupus UK, the 
Primary Care Rheumatology Society and the Royal College of General Practitioners 
which recommends considering a diagnosis of SLE in people with Loss of hair, 
Ulcers-mouth/nose, Pain – musculoskeletal, Unexplained symptoms, signs and 
blood test abnormalities, Sun sensitive rashes or Raynaud’s.(19) 
That people ultimately diagnosed with SLE consult more frequently and with clinical 
features which could be attributable to SLE suggests that there are potential 
opportunities for earlier diagnosis of SLE in primary care. The development of a new 
lupus-like clinical feature should prompt the review of a previous rheumatic 
diagnosis. Current RA diagnostic recommendations include testing serum 
antinuclear antibodies (ANA) and full blood count (complete blood count).(20) A 
positive ANA, lymphopenia or thrombocytopenia should prompt consideration of SLE 
as an alternative diagnosis. Our study therefore reinforces current guidelines (25) 
and suggests that best practice is not always followed. To consider a multi-system 
disease such as SLE in a 10-minute consultation (the usual duration of a 
consultation in the UK) a GP needs to assimilate the current symptoms and consider 
the significance of previous presentations which may seem unconnected. This could 
contribute to diagnostic delay. The lack of rheumatology experience in GP 
training(21) makes educational initiatives such as the “Think LUPUS and Refer" 
campaign essential to increase GPs' awareness of SLE’s protean manifestations. In 
addition, with pressure on primary care, consultations are occurring with allied health 
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professionals who may have limited training in SLE. Predictive models have gained 
increasing popularity in medical practice, particularly for estimating cardiovascular 
risk,(22, 23) osteoporosis risk(24, 25) and earlier diagnosis of malignancy.(26-28) 
Although there have been studies which have considered screening strategies to 
identify undiagnosed cases of SLE in the community (29, 30) there have been no 
previous risk prediction models for earlier diagnosis of SLE. The prediction model 
could be incorporated into primary care software so that it flags patients at risk based 
on symptoms entered contemporaneously and in past consultations. The model 
could prompt review of significant clinical features, to provide a threshold for ANA 
testing and if positive for onward rheumatology referral. The ROC from our prediction 
model compares favourably to the ROC found for the cardiovascular disease, 
osteoporosis and malignancy prediction models; however, comparing a threshold of 
people in the top 10% of risk, our sensitivity and PPV are lower than in these studies. 
This may be due to the rarity of SLE compared to cancer, osteoporosis and 
cardiovascular disease, which would result in a large number of healthy individuals 
being flagged as “at risk”. ANA has good sensitivity but low specificity, therefore 
further examining the antigenic specificities of the ANA might increase its clinical 
utility (31). An alternative screening test such as a more specific or inexpensive 
biomarker for SLE during the period of non-specific symptoms and medical visits 
may enhance early detection. Previous studies have suggested that if diagnosis of 
SLE could be made earlier patient outcomes could be improved and healthcare 
costs reduced(3, 4). It is hoped that tools such as this model may enable earlier 
diagnosis of individuals with clinical features suggestive of SLE.  
The strengths of this study are the large sample size, the generalisability to the UK 
population, and prospective data entry which excludes recall and responder bias. 
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The prediction model methodology was designed to reduce bias by the random 
allocation of cases by practice to development and validation datasets. FPs were 
used to model continuous predictors to account for non-linearity in the relationship 
between the predictor and risk of SLE.(10, 32) The limitations of the study are firstly 
we are reliant on the accuracy of data entered at the GP practice which may have 
been entered incorrectly or incompletely introducing misclassification bias or missing 
data. It may be that features such as fever and lymphadenopathy were due to 
infection rather than early SLE. An increase in infection rate could be due to immune 
system impairment preceding diagnosis which is known to occur following 
diagnosis(33) or could be the environmental trigger for SLE development.(34) While 
ethnicity is an important risk factor for SLE(6) these data are only available for a 
subset of individuals in the CPRD which precluded inclusion in the model. Similarly, 
laboratory test results were not available for a large subset and precluded inclusion 
of positive immunology in the model. Only clinical features in the 5 years preceding 
diagnosis were considered. This time was chosen to maximise participants with 
complete data, but may have excluded important events occurring more than 5 years 
preceding diagnosis. Finally, the model is not diagnostic for SLE, but provides a risk 
stratification which could be used to identify high risk individuals for further 
investigation. As SLE is a very rare disease, less than 1% will develop SLE over a 
period of 5 years, even among those we identify as being high risk. Before use in 
clinical practice the model should undergo clinical and economic evaluation.(32) The 
cost of ANA testing and referral of false positives needs to be balanced against the 
number of SLE cases that would be diagnosed earlier with the prospect of improved 
clinical outcomes.(35)  
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In future, additional variables could be incorporated in the model such as ethnicity 
which may be available in future CPRD releases. Clinical features more than 5 years 
preceding diagnosis could be investigated, along with past exposure to infections, 
immunisations and presentation with further clinical features. 
In conclusion, people subsequently diagnosed with SLE consult their GP more 
frequently and with clinical features within the SLE spectrum in the 5 years prior to 
diagnosis. Early clinical features may be mild and common, but presentation with two 
or more features should prompt clinical review and consideration of investigation 
such as with ANA. A risk prediction model has been developed and validated which 
may assist this decision-making process in future following further evaluation.  
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Tables 
Table 1 Dataset characteristics 
 Cases Controls P value 
Development dataset (n=8,695)    
Total number of cases 1,739 6,956  
Gender: number of females (%) 1,465 (84.2) 3,515 (50.5) <0.001a 
Mean age at diagnosis, years (SD) 50.5 (15.9) 48.6 (18.1) 0.0001b 
Median time before index date, 
years (IQR) 
6.75 (3.15-
11.23) 
6.76 (3.22-
11.16) 
0.97c 
    
Validation dataset (n= 1,831,747)    
Total number of cases 365 1,831,382  
Gender: number of females (%) 312 (85.5) 937,484 
(51.2) 
<0.001a 
Median age at start of follow-up, 
years (IQR) 
43.5 (33.4-
53.8) 
40.1 (28.2-
56.3) 
0.006c 
Median follow-up time, years 
(IQR)* 
2.75 (1.83-
3.81) 
5 (3.15-5.00) <0.001 
* Follow-up was truncated at 5-years or SLE diagnosis in the validation cohort. aChi-
squared test, bStudent’s t-test, cWilcoxon rank-sum test.  
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Table 2 Odds ratios for clinical features in the 5 years prior to diagnosis 
Variable Control
s (%) 
N=6956 
Cases 
(%) 
N=1739 
Univariable odds 
ratio (95%CI) 
P 
value 
Odds ratio adjusted 
for age, gender and 
consultation rate 
(95% CI) 
P 
value 
Clinical 
feature 
          
Arthritis or 
arthralgia 
727 
(10) 
622 
(36) 
4.77 (4.21 5.40) <0.00
1 
3.32 (2.89 3.80) <0.001 
Rash 685 
(10) 
744 
(43) 
6.84 (6.05 7.74) <0.00
1 
5.60 (4.89 6.41) <0.001 
Fatigue 472 (7) 291 
(17) 
2.76 (2.36 3.23) <0.00
1 
1.64 (1.38 1.95) <0.001 
Alopecia 57 (1) 66 (4) 4.77 (3.33 6.83) <0.00
1 
3.31 (2.25 4.87) <0.001 
Sicca 86 (1) 102 (6) 4.97 (3.72 6.66) <0.00
1 
2.70 (1.93 3.78) <0.001 
Raynaud’s 21 (0) 77 (4) 15.2
9 
(9.41 24.85) <0.00
1 
12.2
8 
(7.28 20.73) <0.001 
Serositis 59 (1) 72 (4) 5.05 (3.56 7.15) <0.00
1 
3.13 (2.12 4.64) <0.001 
Nephrotic 
syndrome 
1 (0) 8 (0) 32.1
2 
(4.02 257.0
1) 
<0.00
1 
42.0
0 
(4.82 366.3
6) 
<0.001 
General non- 101 (1) 80 (5) 3.27 (2.43 4.41) <0.00 1.77 (1.27 2.47) <0.001 
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specific 
symptoms 
1 
Myalgia or 
myositis 
0 (0) 0 (0) - - - - - - - - 
Fever 62 (1) 51 (3) 3.36 (2.31 4.88) <0.00
1 
2.81 (1.83 4.33) <0.001 
Lymphadenopa
thy 
74 (1) 54 (3) 2.98 (2.09 4.25) <0.00
1 
2.02 (1.36 2.99) <0.001 
Abnormal 
weight loss 
26 (0) 21 (1) 3.26 (1.83 5.80) <0.00
1 
2.33 (1.20 4.52) 0.01 
Mouth ulcers 64 (1) 58 (3) 3.71 (2.59 5.32) <0.00
1 
2.64 (1.76 3.96) <0.001 
Peripheral 
oedema 
323 (5) 151 (9) 1.95 (1.60 2.39) <0.00
1 
1.32 (1.04 1.67) 0.02 
Proteinuria 32 (0) 13 (1) 1.63 (0.85 3.11) 0.14 0.98 (0.46 2.09) 0.96 
Thrombosis 50 (1)  58 (3) 4.76 (3.25 6.98) <0.00
1 
3.38 (2.18 5.23) <0.001 
Headache 648 (9) 296 
(17) 
2.00 (1.72 2.32) <0.00
1 
1.13 (0.96 1.33) 0.16 
Depression 784 
(11) 
348 
(20) 
1.97 (1.71 2.26) <0.00
1 
1.07 (0.92 1.26) 0.38 
Seizure 20 (0) 13 (1)  2.61 (1.30 5.26) 0.01 1.87 (0.82 4.27) 0.14 
Psychosis 9 (0) 2 (0) 0.89 (0.19 4.11) 0.88 1.00 (0.17 6.00) 1.00 
Confusion 27 (0) 10 (1) 1.48 (0.72 3.07) 0.29 1.07 (0.46 2.48) 0.87 
Anaemia 190 (3) 151 (9) 3.38 (2.71 4.22) <0.00 2.17 (1.70 2.77) <0.001 
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1 
Lymphopenia 0 (0) 3 (0) - - - - - - - - 
Thrombocytope
nia 
5 (0) 15 (1) 12.0
9 
(4.39 33.31) <0.00
1 
10.5
4 
(3.18 34.96) <0.001 
Miscarriage 58 (0) 33 (0)  2.30 (1.49 3.54) <0.00
1 
1.32 (0.83 2.09) 0.24 
Transverse 
myelitis 
0 (0) 0 (0) - - - - - - - - 
Family history (FH)           
FH of 
autoimmune 
disease 
181 (3) 61 (4) 1.36 (1.01 1.83) 0.04 0.96 (0.69 1.32) 0.80 
FH of RA 1 (0) 8 (0) 32.1
4 
(4.02 257.1
6) 
<0.00
1 
22.4
3 
(2.65 189.8
4) 
<0.001 
Previous diagnoses          
Chronic fatigue 
syndrome 
12 (0) 19 (1) 6.39 (3.10 13.19) <0.00
1 
2.53 (1.17 5.45) 0.02 
Fibromyalgia 17 (0) 33 (2) 7.89 (4.39 14.20) <0.00
1 
2.56 (1.35 4.84) <0.001 
RA 31 (0) 80 (5) 10.7
7 
(7.09 16.35) <0.00
1 
7.15 (4.52 11.29) <0.001 
Other CTD 22 (0) 112 (6) 21.6
8 
(13.6
9 
34.36) <0.00
1 
15.2
4 
(9.26 25.11) <0.001 
EBV 6 (0) 2 (0) 1.33 (0.27 6.61) 0.73 1.70 (0.30 9.45) 0.55 
CTD=Connective tissue disease, EBV=Epstein-Barr virus, RA=Rheumatoid arthritis 
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Table 3 Odds ratios for clinical features 0-1 and 1- 5 years prior to diagnosis  
Variable Odds ratio for 0-
1years 
N=8691 (95% CI) 
P 
value 
Odds ratio for 1-5yrs 
N=8291 (95% CI) 
P value 
Clinical feature        
Arthritis or arthralgia 8.71 (7.29 10.41) <0.001 3.16 (2.74 3.64) <0.001 
Rash 13.75 (11.4
9 
16.46) <0.001 4.10 (3.56 4.72) <0.001 
Fatigue 3.52 (2.73 4.55) <0.001 2.59 (2.16 3.10) <0.001 
Alopecia 11.60 (6.15 21.88) <0.001 3.38 (2.15 5.31) <0.001 
Sicca 8.81 (5.10 15.22) <0.001 3.72 (2.66 5.22) <0.001 
Raynaud’s 22.01 (10.3
3 
46.89) <0.001 12.58 (6.55 24.19) <0.001 
Serositis 10.84 (5.57 21.09) <0.001 3.46 (2.26 5.30) <0.001 
Nephrotic syndrome 28.09 (3.45 228.47
) 
<0.001 -* - -  
General non-
specific symptoms 
7.05 (4.00 12.44) <0.001 2.64 (1.87 3.72) <0.001 
Fever 6.58 (3.52 12.29) <0.001 2.27 (1.41 3.65) <0.001 
Lymphadenopathy 3.65 (1.96 6.80) <0.001 2.83 (1.85 4.32) <0.001 
Abnormal weight 
loss 
5.16 (1.92 13.88) <0.001 2.75 (1.35 5.58) 0.01 
Mouth ulcers 4.81 (2.69 8.62) <0.001 3.23 (2.06 5.05) <0.001 
Peripheral oedema 2.58 (1.92 3.48) <0.001 1.50 (1.17 1.91) <0.001 
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Proteinuria 1.85 (0.70 4.87) 0.21 1.33 (0.57 3.14) 0.51 
Thrombosis 8.10 (4.15 15.80) <0.001 4.18 (2.63 6.63) <0.001 
Headache 2.80 (2.23 3.53) <0.001 1.72 (1.45 2.03) <0.001 
Depression 2.29 (1.87 2.81) <0.001 1.84 (1.58 2.15) <0.001 
Seizure 2.67 (0.75 9.47) 0.13 2.26 (0.99 5.11) 0.05 
Psychosis 1.00 (0.11 8.95) 1.00 1.00 (0.11 8.95) 1.00 
Confusion 2.81 (1.07 7.38) 0.04 0.67 (0.20 2.26) 0.51 
Anaemia 6.53 (4.59 9.38) <0.001 2.39 (1.83 3.13) <0.001 
Thrombocytopenia *- - -  6.01 (1.70 21.34) 0.01 
Miscarriage 2.58 (1.11 5.97) 0.03 2.60 (1.60 4.22) <0.001 
Previous diagnoses        
Chronic fatigue 
syndrome 
10.05 (3.15 32.07) <0.001 4.91 (2.03 11.87) <0.001 
Fibromyalgia 8.06 (3.44 18.86) <0.001 7.34 (3.51 15.36) <0.001 
RA 27.56 (12.4
3 
61.08) <0.001 7.41 (4.57 12.00) <0.001 
Other CTD 89.94 (28.2
3 
286.52
) 
<0.001 12.19 (7.32 20.30) <0.001 
EBV 1.33 (0.14 12.82) 0.80 1.33 (0.14 12.82) 0.8 
* No OR could be generated for nephrotic syndrome in the 1-5 year period or 
thrombocytopenia in the 0-1 year period as no controls had the clinical feature. 
 
  
Page 33 of 39
John Wiley & Sons, Inc.
Arthritis Care & Research
This article is protected by copyright. All rights reserved.
34 
 
Table 4 Median number of days between clinical feature onset and diagnosis 
Clinical feature Median number of 
days in controls 
(IQR) 
Median number of 
days in cases 
(IQR) 
P value (Mann-
Whitney U test) 
Fatigue 809.5 (386-1271) 729 (344-1239) 0.2907 
Sicca  821 (433-1172) 687.5 (313-1250) 0.3841 
Rash 858 (448-1299) 590 (173-1196) <0.001 
Arthritis or 
arthralgia 
901 (450-1368) 574 (175-1184) <0.001 
Serositis 904 (537-1389) 513.5 (161-1193.5) 0.0031 
Alopecia 750 (440-1370) 475 (143-1155) 0.0217 
Raynaud’s 780 (286-1094) 433 (207-1110) 0.3300 
General non-
specific symptoms 
938 (403-1390) 509 (166-1088.5) 0.0001 
Nephrotic 
syndrome 
94 (94-94) 58.5 (42.5-98.5) 0.4386 
Fever 770 (395-1322) 416 (151-797) 0.0051 
Lymphadenopathy 687 (336-1128) 670.5 (337-1025) 0.9846 
Abnormal weight 
loss 
763.5 (358-915) 495 (262-837) 0.2350 
Mouth ulcers 675.5 (341.5-1239) 504 (255-1036) 0.2363 
Peripheral oedema 904 (393-1376) 553 (243-1237) 0.0004 
Proteinuria 664.5 (244-1276.5) 552 (63-819) 0.2494 
Thrombosis 835 (478-1421) 768 (272-1257) 0.4522 
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Headache 916 (478-1347.5) 703.5 (308.5-
1223.5) 
0.0006 
Depression 959 (522.5-1437.5) 954 (442.5-1419.5) 0.2592 
Seizure 982.5 (647.5-1590) 836 (467-1493) 0.5072 
Psychosis 490 (228-618) 882.5 (158-1607) 1.0000 
Confusion 532 (237-1169) 180 (42-631) 0.1007 
Anaemia 983.5 (496-1336) 503 (151-1010) <0.001 
Thrombocytopenia 729 (710-783) 338 (128-707) 0.0325 
Miscarriage 1124 (445-1480) 917 (637-1499) 0.9605 
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Table 5 Multivariable analysis 
Variable Multivariate mutually 
adjusted odds ratio (95%CI) 
β-
coefficient 
Wald’s p value 
Gender 3.942 3.260 4.767 1.3718 <0.001 
Age at diagnosis 
(FP1)a 
1.006 1.004 1.008 0.0058 0.165 
Age at diagnosis 
(FP2)b 
0.999 0.998 0.999 -0.0013 0.200 
Arthralgia or arthritis 1.872 1.592 2.202 0.6273 <0.001 
Rash 3.036 2.598 3.549 1.1106 <0.001 
Alopecia 1.967 1.193 3.241 0.6763 0.008 
Raynaud’s 8.465 4.106 17.452 2.1359 <0.001 
Fatigue  1.412 1.156 1.725 0.3451 0.001 
Serositis 1.635 1.012 2.641 0.4917 0.044 
Sicca 1.562 1.050 2.324 0.4458 0.028 
Consultation rate 
(FP1)c 
1.000 1.000 1.000 0.0003 <0.001 
Consultation rate 
(FP2)d 
1.561 1.449 1.681 0.4453 <0.001 
Gender*ageFP1 0.998 0.996 1.001 -0.0018 <0.001 
Gender*ageFP2 1.000 1.000 1.001 0.0004 <0.001 
a=age2 b= age2 x ln(age) c= rate-0.5 d= ln(rate) 
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Figure legends: 
Figure 1:a) ROC curve and b) calibration plot in the validation dataset 
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 Figure 1:a) ROC curve and b) calibration plot in the validation dataset 
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